At the time of writing, Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $347.45, up 5.53%. An important factor to consider is whether the stock is rising or falling in short-term value. The MDGL shares have gain 20.40% over the last week, with a monthly amount glided 71.17%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $382. On April 22, 2024, BofA Securities initiated with a Underperform rating and assigned a price target of $150 on the stock. B. Riley Securities upgraded its rating to a Neutral and increased its price target to $270 on March 15, 2024. Citigroup initiated its recommendation with a Buy and recommended $382 as its price target on March 06, 2024. B. Riley Securities downgraded its rating to Sell for this stock on February 26, 2024, but kept the price target unchanged to $155. In a note dated December 20, 2022, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $170 to $250.
For the past year, the stock price of Madrigal Pharmaceuticals Inc fluctuated between $168.25 and $368.29. Currently, Wall Street analysts expect the stock to reach $315.75 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $347.45 at the most recent close of the market. An investor can expect a potential drop of -9.12% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -7.06%, Pretax Profit Margin comes in at -6.69%, and Net Profit Margin reading is -6.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.72 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 329.77 points at the first support level, and at 312.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 358.10, and for the 2nd resistance point, it is at 368.75.
Ratios To Look Out For
It is important to note that Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] has a current ratio of 5.98. On the other hand, the Quick Ratio is 5.93, and the Cash Ratio is 1.31. Considering the valuation of this stock, the price to sales ratio is 104.12, the price to book ratio is 9.75.
Transactions by insiders
Recent insider trading involved Huntsman Carole, Chief Commercial Officer, that happened on Nov 21 ’24 when 688.0 shares were sold. Officer, Carole Huntsman completed a deal on Nov 21 ’24 to buy 688.0 shares. Meanwhile, Director Levy Richard S sold 5000.0 shares on Nov 07 ’24.
